Patent intelligence · US
US 12011502
Compositions and methods of administering baclofen
Compositions and methods of administering baclofen
Patent details — US 12011502
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 18, 2024
- Expiration
- Jun 13, 2044
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Claims
- 12
- CPC classes
- A61K, A61K31/197, A61K9/0019, A61P
Quick answer
US 12011502 (Compositions and methods of administering baclofen) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Jun 18, 2024. Expires Jun 13, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/197, A61K9/0019, A61P, A61P1/00
More from AMNEAL PHARMACEUTICALS LLC
Related pharmaceutical patents in our USPTO index.
-
US 12383522
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 12370163
Levodopa dosing regimen
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12233166
Extended release compositions comprising pyridostigmine
granted
Frequently asked questions
What is US patent 12011502?
US 12011502 (Compositions and methods of administering baclofen) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Jun 18, 2024. Expires Jun 13, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12011502?
AMNEAL PHARMACEUTICALS LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 12011502 expire?
Our index shows an expiration date of Jun 13, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.